• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide
【24h】

Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide

机译：长期施用替莫唑胺治疗胶质母细胞瘤患者的存活分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China. A total of 75 patients with newly diagnosed glioblastoma at the Department of Radiation Oncology, Shenzhen People's Hospital between August 2008 and August 2016 were retrospectively evaluated during analysis. A propensity-matched analysis was performed to balance the basic characteristics of patients between compared groups. Kaplan–Meier method and Cox proportional hazards model were used to assess progression-free survival (PFS) and overall survival (OS) of patients receiving 6 adjuvant TMZ cycles compared with patients treated with more than 6 cycles. Twenty of 75 patients received more than 6 cycles of TMZ, and the other 55 patients were treated with a median of 6 cycles ranging from 1 to 6. The patients with long-term administration of TMZ had better OS (47.0 months, 95% CI 20.0–73.9 vs 20.6 months, 95% CI 17.9–23.2, P = .014) but not PFS (17.0 months, 95% CI 10.1–24.5 vs 14.2 months, 95% CI 11.8–16.6, P = .133). Balancing the clinical factors with a propensity-matched analysis also showed the significant advantage of prolonged TMZ application in terms of OS but not PFS. Prolonged administration of TMZ beyond 6 cycles did demonstrate survival benefits for patients with initially diagnosed glioblastoma .
机译：该分析旨在调查替代灭菌毒物（TMZ）的长期施用是否对中国胶质母细胞瘤的患者索赔了生存优势。在分析期间回顾性评估了在2008年8月至2016年8月期间，在深圳人民医院肿瘤肿瘤系中共有75例新诊断的新诊断的胶质母细胞瘤。进行竞争匹配的分析以平衡比较组之间患者的基本特征。与用超过6个循环处理的患者相比，Kaplan-Meier方法和Cox比例危害模型用于评估接受6辅助TMZ循环的患者的无进展存活（PFS）和总存活（OS）。 20名75名患者接受了超过6个循环的TMZ，另外55名患者被中位数从1至6次。患有长期施用TMZ的患者具有更好的OS（47.0个月，95％CI 95％ 20.0-73.9 VS 20.6个月，95％CI 17.9-23.2，P = .014）但不是PFS（17.0个月，95％CI 10.1-24.5 VS 14.2个月，95％CI 11.8-16.6，P = .133）。平衡具有倾向匹配的分析的临床因素还表明，在OS的OS但不是PFS方面的延长TMZ应用的显着优势。长期施用TMZ超过6个循环确实表现出初始诊断的胶质母细胞瘤的患者的存活益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号